Literature DB >> 2310690

Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis.

A Chott1, H Gisslinger, J Thiele, E Fritz, W Linkesch, T Radaszkiewicz, H Ludwig.   

Abstract

Interferon(rIFN)-alpha, a successful therapeutic agent in the control of thrombocytosis, has been shown to suppress human megakaryopoiesis. We investigated bone marrow biopsies from 12 patients with thrombocytosis due to chronic myeloproliferative disorders. Prior to treatment as well as during rIFN-alpha-2c therapy, several morphometric parameters of megakaryopoiesis were evaluated. Megakaryocyte density decreased significantly in all patients, megakaryocyte size decreased in polycythaemia vera, agnogenic myeloid metaplasia, and essential thrombocythaemia, but increased in chronic myeloid leukaemia. The various changes observed during therapy indicate an inhibitory effect of rIFN-alpha-2c on megakaryopoiesis and suggest a selective influence on megakaryocytes at various stages of maturation. Increased numbers of pyknotic (bare) nuclei may reflect a shortening of megakaryocyte life-span. No remarkable changes were found in the fibre content of the bone marrow.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310690     DOI: 10.1111/j.1365-2141.1990.tb02531.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Treatment of polycythemia vera with recombinant interferon.

Authors:  Richard T Silver
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.

Authors:  Marco Pizzi; Richard T Silver; Ariella Barel; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-08-14       Impact factor: 7.842

3.  Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.

Authors:  Min Lu; Jiapeng Wang; Yan Li; Dmitriy Berenzon; Xiaoli Wang; John Mascarenhas; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

4.  Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term alpha-IFN treatment.

Authors:  S Sacchi; A Tabilio; P Leoni; A Riccardi; A Vecchi; C Messora; L Bensi; F Falzetti; S Rupoli; G Ucci
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

5.  Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.

Authors:  Min Lu; Wei Zhang; Yan Li; Dmitriy Berenzon; Xiaoli Wang; Jiapeng Wang; John Mascarenhas; Mingjiang Xu; Ronald Hoffman
Journal:  Exp Hematol       Date:  2010-03-18       Impact factor: 3.084

Review 6.  Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Authors:  Aziz Nazha; Aaron T Gerds
Journal:  Oncologist       Date:  2016-03-14

7.  Nucleolar organizer regions of megakaryocytes in chronic myeloproliferative disorders.

Authors:  A Matolcsy; R Nádor; E Wéber; T Kónya
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 8.  Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Authors:  Richard T Silver
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 4.213

9.  Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Authors:  Lucia Masarova; C Cameron Yin; Jorge E Cortes; Marina Konopleva; Gautam Borthakur; Kate J Newberry; Hagop M Kantarjian; Carlos E Bueso-Ramos; Srdan Verstovsek
Journal:  Exp Hematol Oncol       Date:  2017-11-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.